Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer
Innate Pharma SA (NASDAQ: IPHA) presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab in patients with advanced Sézary syndrome, a form of T cell lymphoma.
At the time of data cut-off (April 29, 2022), the Intention To Treat (ITT1) population included 37 post-mogamulizumab patients, and 35 patients were Evaluable for Efficacy (EES2).
Related: AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer.
The global objective response rate (ORR) in the ITT population was 21.6% (8/37). ORR in the blood was 37.8%, with 21.6% (8/37) achieving complete response (CR). ORR in the skin was 35.1%.
In the EES population, global ORR was 22.9% (8/35). ORR in the blood was 40.0%, and ORR in the skin was 37.1%.
In line with previous observations, lacutamab demonstrated a favorable safety profile.
Grade ≥ 3 Treatment-related (TR) Treatment-Emergent Adverse events (TEAEs) were observed in 6/37 (16.2%) patients.
Price Action: IPHA shares are up 4.72% at $2.22 on the last check Monday.
See more from Benzinga
Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting
Biotricity Files FDA 510(k) For Expanded Use Of Its Biotres Cardiac Monitoring Device
Donald Trump's Wife Melania Was Convinced He Was 'Screwing Up,' Best-Selling Book Reveals
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.